TARPLIN STRATEGIES LLC for GENENTECH, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Participated in several meetings and discussions on evolving principles/specifications for health care reform bills being developed by congressional committees. Discussions included the following subjects: government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Medicare/Medicaid MMM
Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - government reimbursement for biotherapeutics S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Pharmacy PHA
H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Medical/Disease Research/Clinical Labs MED
Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - funding for comparative effectiveness research. Draft legislation - the Comparative Effectiveness Research Act - authorization for comparative effectiveness research. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ROCHE HOLDING, LTD. | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.